Pulmonary Manifestations of Polymyositis/Dermatomyositis

Robert W. Hallowell, MD1 Dana P. Ascherman, MD2 Sonye K. Danoff, MD, PhD1,3

1 Division of Pulmonary and Critical Medicine, John Hopkins School of Medicine, Baltimore, Maryland
2 Division of Rheumatology, University of Miami Health System, Miami, Florida
3 Johns Hopkins Myositis Center, John Hopkins School of Medicine, Baltimore, Maryland

Abstract

Keywords

The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

The Idiopathic Inflammatory Myopathies

The idiopathic inflammatory myopathies (IIMs) are a group of relatively rare connective tissue diseases marked by varying degrees of muscle inflammation. The main forms of adult IIM include polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM). Amyopathic DM (ADM) contains the classic skin findings of DM in the absence of overt muscle involvement. With the exception of IBM, each of these entities can present with a wide range of clinical findings involving multiple organ systems, including the heart, skin, joints, and lung.

Pulmonary involvement in DM/PM is associated with worse outcomes and increased mortality and is the primary reason for hospital admission in a majority of patients. Depending on the methods used to detect interstitial lung disease (ILD), its prevalence in patients with DM/PM ranges from 19.9 to 78%,2,5–9 and its presentation can range from fulminant to subclinical.10,11 Nevertheless, ILD is not one of the original criteria used by Bohan and Peter to diagnose DM or PM.12,13 Although it most frequently develops during or after the appearance of muscle inflammation, ILD precedes the diagnosis of DM/PM in 13 to 37.5% of patients4,2,4,14,15 and tends to be associated with higher rates of fever and joint involvement.7

The Antisynthetase Syndrome

In recent years, several myositis-specific autoantibodies (MSAs) have been discovered: antisignal recognition particle (anti-SRP) antibodies, anti-Mi-2 antibodies, anti-PM/Scl antibodies, anti-aminocyl-tRNA synthetase (ARS) antibodies, anticlinically ADM-140-kDa polypeptide antibodies (anti-CADM-140 antibodies or melanoma differentiation–associated gene 5 [MDA-5]), and anti-155/140-kDa polypeptide antibodies (anti-155/140 antibodies)16–19 (Table 1). Among these MSAs, ARS antibodies target the cytoplasmic ARS enzymes that are responsible for loading each tRNA with a specific amino acid before it is incorporated into a growing peptide at the level of the ribosome.20
amino acids, each of which has a cognate tRNA synthetase. To date, antibodies specific for eight of these synthetases have been detected and implicated in connective tissue disease: antihistidyl- (anti-Jo-1), antithreonyl- (anti-PL-7), antialanyl- (anti-PL-12), antiisoleucyl- (anti-OJ), antiisoleucyl- (anti-OJ), antiasparaginyl- (anti-KS), antiglycyl- (anti-EJ), antiphenylalanyl- (anti-Zo), and anti-yrosyl-tRNA- (anti-YRS) tRNA synthetase. The presence of a DARS antibody in conjunction with inflammatory myositis or ILD has collectively come to be known as the antisynthetase syndrome, with additional clinical features that can include nonerosive arthritis, fever, mechanic’s hands, and Raynaud phenomenon. While the concomitant presence of other autoimmune antibodies is not uncommon, overlap between the ARS antibodies themselves is rare. Specific ARS antibodies are associated with different subphenotypes characterized by a varying prevalence of myositis, ILD, and other clinical manifestations of connective tissue disease. In general, the presence of any ARS antibody confers a substantially higher risk for developing ILD, with multiple studies demonstrating a prevalence of 67 to 100% depending on the specific antibody identified. Of the eight known ARS antibodies, anti-Jo-1 is the most common, being present in 15 to 30% of patients with IIM. Clinically evident myositis occurs in greater than 50% of patients with the anti-Jo-1 antibody, and ILD is also extremely common, occurring in 67 to 86% of cases. Collectively, anti-PL-7, anti-PL-12, anti-KS, and anti-OJ confer the greatest risk of developing ILD, and patients with these antibodies are also more likely to have ILD either in isolation or preceding the diagnosis of DM/PM. For example, one study demonstrated that the rates of ILD existing in the absence of clinically evident myositis were 33, 63, and 77% in patients positive for anti-PL-12, anti-KS, and anti-OJ, respectively. In another study, 35% of patients with anti-PL-7 antibodies had ILD that preceded the diagnosis of antisynthetase syndrome.

### Table 1 Myositis-specific antibodies

<table>
<thead>
<tr>
<th>Myositis-associated antibodies</th>
<th>Target antigen</th>
<th>Prevalence in IIM</th>
<th>Clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Ro52</td>
<td>Extractable nuclear antigen Ro52</td>
<td>13–26%</td>
<td>Associated with more severe ILD</td>
</tr>
<tr>
<td>Anti-MDA-5</td>
<td>MDA-5 RNA helicase</td>
<td>20–25%</td>
<td>Skin ulceration; CADM; rapidly progressing/acute interstitial pneumonitis</td>
</tr>
<tr>
<td>Anti-155/140</td>
<td>155/140-kDa polypeptides</td>
<td>7–16%</td>
<td>Highest risk of malignancy, lower risk of ILD</td>
</tr>
<tr>
<td>Anti-SRP</td>
<td>Cytoplasmic signal recognition particle</td>
<td>5–6%</td>
<td>Severe myopathy and weakness; risk of ILD is not increased</td>
</tr>
<tr>
<td>Anti-Mi-2</td>
<td>Nuclear helicase protein</td>
<td>14%</td>
<td>Milder myopathy and classic DM findings; risk of ILD is not increased</td>
</tr>
</tbody>
</table>

### Table 2 Antisynthetase antibodies

<table>
<thead>
<tr>
<th>Antisynthetase antibodies (ARS)</th>
<th>Target antigen</th>
<th>Prevalence in IIM</th>
<th>% of ARS antibodies detected</th>
<th>Clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Jo-1</td>
<td>Histidyl-tRNA synthetase</td>
<td>8–18%</td>
<td>36–88%</td>
<td>Classic DM, ILD</td>
</tr>
<tr>
<td>Anti-EJ</td>
<td>Glycyl-tRNA synthetase</td>
<td>5–10%</td>
<td>7–23%</td>
<td>Classic DM and CADM, ILD</td>
</tr>
<tr>
<td>Anti-PL-7</td>
<td>Threonyl-tRNA synthetase</td>
<td>5%</td>
<td>9–25%</td>
<td>Classic DM, ILD</td>
</tr>
<tr>
<td>Anti-OJ</td>
<td>Isoleucyl-tRNA synthetase</td>
<td>3%</td>
<td>5–8%</td>
<td>Isolated ILD</td>
</tr>
<tr>
<td>Anti-PL-12</td>
<td>Alanyl-tRNA synthetase</td>
<td>1%</td>
<td>2–11%</td>
<td>Isolated ILD, CADM</td>
</tr>
<tr>
<td>Anti-KS</td>
<td>Asparaginyl-tRNA synthetase</td>
<td>1%</td>
<td>4–8%</td>
<td>Isolated ILD</td>
</tr>
<tr>
<td>Anti-Zo</td>
<td>Phenylalanyl-tRNA synthetase</td>
<td>&lt; 1%</td>
<td>&lt; 1%</td>
<td></td>
</tr>
<tr>
<td>Anti-YRS</td>
<td>Tyrosyl-tRNA synthetase</td>
<td>&lt; 1%</td>
<td>&lt; 1%</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ARS, antiaminoacyl-tRNA synthetase; CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease.

Abbreviations: CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; MDA-5, melanoma differentiation-associated gene 5; SRP, signal recognition particle.

*Prevalence is reported in patients with DM/CADM only, as anti-MDA-5 antibodies are rarely found in PM.
Anti-MDA-5 (Anti-CADM-140) Antibodies

In addition to the ARS antibodies, a 140-kDa cytoplasmic protein was identified as being highly associated with clinically ADM (C-ADM) and subsequently named anti-CADM-140.\textsuperscript{28,36,37} In 2009, Sato et al discovered that anti-CADM-140 reacts with an RNA helicase encoded by MDA-5, and the antibody was subsequently renamed as anti-MDA-5.\textsuperscript{36} Despite its original name, anti-MDA-5 antibodies can be associated with clinically active myositis. Anti-MDA-5 often produces a phenotype that mimics the antisynthetase syndrome,\textsuperscript{28,37,38} however, it is also associated with characteristic skin findings including tender palmar papules and deep ulcerations with punched out borders and necrosis (\textsuperscript{–} Fig. 2). Furthermore, anti-MDA-5 antibodies are rarely found in other connective tissue diseases such as rheumatoid arthritis and systemic lupus erythematosus.\textsuperscript{37}

Anti-MDA-5 antibodies confer a high risk for the development of ILD and have been associated with rapidly progressive and acute/subacute interstitial pneumonia in several cohorts.\textsuperscript{16,37–45} Furthermore, the presence of anti-MDA-5 antibodies represents an individual risk factor for death from ILD in DM patients.\textsuperscript{37,41,42,44} In one study, anti-MDA-5 antibody levels correlated with the severity of high-resolution computed tomography (CT) scores in patients with ILD.\textsuperscript{28,38,39} In addition, patients with anti-MDA-5 levels greater than 500 units/mL were found to have more treatment-resistant lung disease and skin ulcerations, with a higher rate of respiratory failure and death compared with patients with levels less than 500 units/mL.\textsuperscript{38} Overall, then, anti-MDA-5 titers seem to correlate with treatment response and survival in patients with ILD.\textsuperscript{43,46,47}

The pathophysiology linking anti-MDA-5 titers with the severity of ILD is poorly understood, though some have suggested a relationship to underlying vascular pathology.\textsuperscript{38,39} MDA-5 is an RNA helicase that recognizes the double stranded RNA of picornaviruses to induce the production of type-1 interferons and tumor necrosis factor as part of the innate antiviral immune response.\textsuperscript{37,43} One hypothesis postulates that anti-MDA-5 antibodies are somehow generated during a viral infection,\textsuperscript{36} perhaps through an aberrant, overly exuberant immune response.

Anti-155/140 Antibodies

The third group of myositis-specific antibodies includes those targeting 155/140-kDa polypeptides (anti-155/140 antibodies) corresponding to TIF1 transcription factors. Anti-155/140 antibodies are found in 13 to 16% of DM/PM patients,\textsuperscript{17,40,45} and they are highly associated with the presence of malignancy in adults.\textsuperscript{17,40} However, in contrast to ARS and anti-MDA-5 antibodies, anti-155/140 antibodies are associated with a lower risk of ILD.\textsuperscript{17,42}

Anti-PM/Scl and Anti-Ro Antibodies

Other antibodies associated with DM/PM and ILD include anti-PM/Scl and anti-Ro52. When present in myositis patients, anti-PM/Scl antibodies are associated with clinical features resembling those of the antisynthetase syndrome.\textsuperscript{48–50} ILD is present with a high frequency in anti-PM/Scl positive patients, though pulmonary disease tends to occur after the appearance of other connective tissue disease manifestations.\textsuperscript{50}

Anti-Ro-52 is an antibody found in numerous connective tissue diseases—including systemic lupus erythematosus, mixed connective tissue disease, and DM/PM—and its presence is associated with an increased risk of ILD.\textsuperscript{51} Anti-Ro-52 is commonly found in patients with the antisynthetase syndrome\textsuperscript{52} and has been reported in 19% of patients with ARS antibodies\textsuperscript{27} as well as patients with other myositis-specific antibodies. Overall, 20% of patients with DM/PM express anti-Ro-52 antibodies,\textsuperscript{52,53} though the frequency of anti-Ro-52 is higher among those with ILD; in fact, one cohort reported that 90% of DM/PM patients with ILD were reactive to anti-Ro-52.\textsuperscript{51} Furthermore, in a cohort of anti-Jo1 positive patients, the presence of anti-Ro52 antibodies was associated
with higher total high-resolution computed tomography (HRCT) scores\textsuperscript{54} as well as worse myositis, joint involvement, and survival.\textsuperscript{32} Collectively, these observations suggest that the coexistence of anti-Ro52 and anti-Jo-1 antibodies may be predictive of a more aggressive disease course.

**Anti-SRP and Anti-Mi-2 Antibodies**

Anti-SRP antibodies recognize the SRP, a cytoplasmic protein that regulates the movement of proteins through the endoplasmic reticulum.\textsuperscript{55,56} These autoantibodies are found in roughly 5\% of IIM patients\textsuperscript{18,19} and are associated with severe myositis marked by profound weakness and highly elevated muscle enzymes. Unlike antisynthetase antibodies, anti-SRP antibodies do not confer an increased risk of developing ILD, and some authors even contend that the risk of pulmonary disease is actually decreased in anti-SRP-positive patients when compared with myositis controls.\textsuperscript{55–58}

Mi-2 is a nuclear helicase protein comprising the nucleosome-remodeling deactetylase complex involved in DNA transcription. Unlike anti-SRP antibodies, anti-Mi-2 antibodies are more common in patients with DM than PM and are often associated with less severe muscle involvement. However, like anti-SRP antibodies, they are not associated with an increased risk of myositis-associated ILD.\textsuperscript{55,59,60}

**Genetic Factors**

There is growing evidence that genetic factors may influence the development of ILD in patients with DM/PM and the antisynthetase syndrome. In one cohort of British patients with DM/PM, ILD was more common in patients of black ethnicity.\textsuperscript{9} In addition, numerous reports have indicated a higher prevalence of rapidly progressive ILD in cohorts from Eastern Asia with ADM and anti-MDA-5 antibodies,\textsuperscript{9,10,30} with many cases that have proven refractory to immunosuppressive therapy.\textsuperscript{10} However, in an American cohort of anti-MDA-5 positive patients, most cases of ILD were responsive to immunosuppressive therapy.\textsuperscript{28} While all of these studies are limited by small sample size, they may indicate that various autoimmune antibodies can be associated with different phenotypes in different ethnic backgrounds.

Genetic studies have identified an association between the DRB1*03-DQA1*05-DQB1*02 haplotype and the presence of both ARS antibodies and ILD. Conversely, HLADRBI*07DQA1*02-DQB1*02 is associated with a decreased risk of ILD.\textsuperscript{61} Furthermore, while HLA-DRBI*0301 is relatively common in Caucasians with ARS antibody-positive DM/PM, the frequency of HLA-DRB1*0301 is low in the Japanese population. However, HLA-DRB1*0405, found in 20\% of the Japanese population, is highly associated with anti-MDA-5 antibody-positive DM and associated ILD.\textsuperscript{30}

**CT Imaging in DM/PM and the Antisynthetase Syndrome**

The CT findings of patients with DM/PM and the antisynthetase syndrome can be highly variable depending on the severity and acuity of their pulmonary symptoms. While patients presenting with acute ILD tend to have ground glass opacities and consolidations, patients presenting with a more chronic course of ILD have more evidence of reticulation and honeycombing.\textsuperscript{9} In both groups, parenchymal abnormalities are predominantly in a basilar and subpleural distribution.\textsuperscript{4,14,21} Interestingly, ground glass and reticular opacities can be associated with fatal cases of ILD, while a consolidative pattern is associated with nonfatal disease.\textsuperscript{5,62,63} Other patterns described with less frequency in DM/PM and the antisynthetase syndrome include traction bronchiectasis and subpleural condensations.\textsuperscript{5,64} (\textsuperscript{\textcopyright} Fig. 3).

**Pulmonary Function Testing**

Patients with ILD associated with myositis and the antisynthetase syndrome tend to have a restrictive pattern on pulmonary function tests (PFTs) with generally mild reductions in forced vital capacity (FVC, 70–79\% predicted) and mild to moderate reductions in the diffusing capacity for carbon monoxide (DLCO); however, a wide range has been reported, and there have been no definitive studies to suggest that specific myositis-associated antibodies are linked with more severe PFT abnormalities.\textsuperscript{4,8,15,24,37,64–68} Total lung capacity (TLC) and FVC have been used to monitor disease progress as well as therapeutic response,\textsuperscript{4,8,15,69} and there is evidence that a lower FVC and DLCO at the time of ILD diagnosis predict a worse prognosis.\textsuperscript{57,69} However, PFTs in patients with myositis must be interpreted with caution, since respiratory muscle weakness alone can result in restrictive physiology, even in the absence of ILD. Conversely, PFTs may appear to improve despite persistent or worsening pulmonary disease as muscle weakness responds to corticosteroid or immunomodulatory therapy.\textsuperscript{69}

**Pneumomediastinum**

Spontaneous pneumomediastinum is a rare complication of DM associated with significant morbidity and mortality. One review reported that one-quarter of patients died in the 1st month, with a cumulative survival rate of only 64\% at 1 year and 55\% at 2 years.\textsuperscript{70} Although pneumomediastinum in patients with PM has been reported, the vast majority of cases have occurred in patients with DM.\textsuperscript{70–76} The pathogenesis of pneumomediastinum in patients with myositis is poorly understood, though it is speculated to result from the rupture of subpleural blebs that occur with ILD, leading to dissection of air around perivascular sheaths and into the mediastinum.\textsuperscript{75} However, there have been reports of pneumomediastinum occurring in DM patients without known ILD,\textsuperscript{71} and some have speculated that vasculopathy may also be playing a role by disrupting the bronchial mucosal barrier and causing subpleural infarctions.\textsuperscript{71,75}

**Pathology**

Open lung biopsy is often not performed in patients with DM/PM or the antisynthetase syndrome, partly because the
results of such a biopsy may not influence the choice of immunosuppressant therapy. However, multiple studies have reported limited pathology with mixed results. Marie et al studied a cohort of 107 patients with DM/PM and found nonspecific interstitial pneumonia (NSIP) in 61%, cryptogenic organizing pneumonia (COP) in 22%, and usual interstitial pneumonia (UIP) in 17% of the 41 biopsy samples available. The prevalence of various MSAs was not evaluated in this study, though there is some evidence that various ARS antibodies may not necessarily be associated with any particular histologic pattern of ILD. For instance, Koreeda et al reported biopsies on four patients positive for different ARS antibodies, each of which demonstrated an NSIP pattern with lymphocytes and plasma cells infiltrating the interstitium. Furthermore, biopsies from three patients with idiopathic interstitial pneumonia in the setting of anti-Oj antibody reactivity demonstrated three different histologic patterns: NSIP, UIP, and COP. In another study, three out of five biopsies in patients with anti-PL-7 antibodies demonstrated a UIP pattern, while NSIP was the most common pattern in a group of 22 patients with anti-Jo-1 antibodies. Further demonstrating the high degree of variability in these studies, Richards et al showed that UIP was three times more common than NSIP in another cohort of anti-Jo-1 positive patients. Moreover, an additional study reported that four out of five patients with myositis who developed respiratory failure were found to have diffuse alveolar damage on biopsy with a mortality rate of 100%. Therefore, while it is possible that associations exist between specific antibodies and certain histologic patterns, no studies to date have been large enough to conclusively determine the nature of such associations.

**Treatment**

Steroids remain the first-line therapy for ILD in patients with DM/PM or the antisynthetase syndrome. Oral regimens include 1 mg/kg of prednisone daily, often following an initial pulse of intravenous methylprednisolone at a dose of 1,000 mg daily for 3 days in severe cases. While some patients with ILD and myositis will have an adequate response to corticosteroid monotherapy, the need for additional immunosuppression, especially in the case of rapidly progressing acute/subacute ILD, is common. Interestingly, the presence of ARS antibodies may predict a better ILD response to steroids in myositis patients, though additional factors influencing the outcome of steroid treatment include the relative timing of ILD and myositis onset (Table 3). Azathioprine has been used in patients with anti-Jo-1 ILD either as maintenance therapy following cyclophosphamide or as a steroid-sparing agent in patients receiving concomitant prednisone, with roughly 58% of patients demonstrating either resolution or significant improvement in pulmonary status.

The safety of mycophenolate mofetil for the treatment of numerous connective tissue diseases is well established, though its efficacy for ILD remains in question. There have been reports of DM-ILD patients with either significant improvement or complete resolution of their ILD following treatment with mycophenolate mofetil, including a case series of four patients who had improvement with mycophenolate mofetil after treatment with steroids and azathioprine proved to be ineffective.
Cyclophosphamide, a nitrogen mustard alkylating agent, has also been used with some efficacy in treating myositis-related ILD. \textsuperscript{15,80} One study by Yamasaki et al used an intravenous dose of 300 to 800 mg/m\textsuperscript{2} at least six times every 4 weeks to treat refractory ILD and demonstrated both functional and radiographic improvement in the majority of patients. \textsuperscript{83} Another study reported either resolution or a significant improvement in pulmonary status in 72\% of anti-Jo-1 ILD patients treated with cyclophosphamide based on symptoms, PFTs, and HRCT imaging. \textsuperscript{15} However, Ingegnoli et al observed improvement in only four of eight anti-Jo-1 PM ILD patients treated with a cyclophosphamide pulse plus steroids. \textsuperscript{84}

Several studies have also highlighted a possible benefit of using cyclosporine A (CsA) to treat steroid-resistant ILD. \textsuperscript{78,85} Takada et al found that after 4 weeks of treatment, essentially all DM and PM patients diagnosed as having chronic ILD had at least some response to a combination of CsA and corticosteroids. Unfortunately, their results were less promising in those patients presenting with acute ILD; after 4 weeks of combination treatment, fewer than 50\% of these patients had a partial response, and there were two reported deaths. Moreover, remission by the last clinical evaluation was only observed in roughly half the acute ILD patients, with an additional three deaths recorded over time. Interestingly, however, this study also seemed to suggest that patients who received a combination of CsA and steroids up front had better outcomes than those who initially received only steroids. \textsuperscript{85} In contrast, Ingegnoli et al reported that five out of seven patients with anti-Jo-1-positive PM who were treated with CsA manifested CT evidence of worsening ILD, though the acuity of their ILD was not reported. \textsuperscript{84}

There is evidence that the related calcineurin inhibitor tacrolimus may be superior to CsA, as several patients in the Takada study who had persistently active ILD despite prednisolone and CsA therapy demonstrated a prompt response to tacrolimus. \textsuperscript{85} Other reports have also demonstrated the efficacy of tacrolimus in the treatment of anti-Jo-1-associated ILD. \textsuperscript{86}

### Table 3: Studies reporting various treatment modalities for DM/PM-associated ILD

<table>
<thead>
<tr>
<th>Study lead author, year</th>
<th>Total no. of ILD patients</th>
<th>CS alone</th>
<th>CYC</th>
<th>AZA</th>
<th>MMF</th>
<th>CsA</th>
<th>Tacro</th>
<th>RTX</th>
<th>MTX</th>
<th>IVIG</th>
<th>Pulmonary improvement, stabilization (%)</th>
<th>Mortality, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kono et al, 2000 \textsuperscript{71}</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>NR</td>
<td>1 (25)</td>
<td>1 (25)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee et al, 2002 \textsuperscript{70}</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>NR</td>
<td>5 (100)</td>
<td>5 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fujisawa et al, 2005 \textsuperscript{85}</td>
<td>28</td>
<td>7</td>
<td>8</td>
<td>10</td>
<td>NR</td>
<td>8 (29)</td>
<td>8 (29)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kameda et al, 2005 \textsuperscript{80}</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>NR</td>
<td>5 (50)</td>
<td>5 (50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Takada et al, 2005 \textsuperscript{85}</td>
<td>32</td>
<td>8</td>
<td>32</td>
<td>5</td>
<td>19 (59)</td>
<td>19 (59)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilkes et al, 2005 \textsuperscript{86}</td>
<td>13</td>
<td>2</td>
<td>5</td>
<td>13</td>
<td>13 (100)</td>
<td>13 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ye et al, 2007 \textsuperscript{71}</td>
<td>21</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>NR</td>
<td>12 (57)</td>
<td>12 (57)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yamasaki et al, 2007 \textsuperscript{83}</td>
<td>17</td>
<td>5</td>
<td>17</td>
<td>1</td>
<td>2</td>
<td>NR</td>
<td>17 (17)</td>
<td>17 (17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ideura et al, 2007 \textsuperscript{64}</td>
<td>18</td>
<td>3</td>
<td>2</td>
<td>13</td>
<td>3</td>
<td>13 (72)</td>
<td>3</td>
<td>13 (72)</td>
<td>13 (72)</td>
<td>5 (28)</td>
<td>5 (28)</td>
<td></td>
</tr>
<tr>
<td>Fathi et al, 2008 \textsuperscript{8}</td>
<td>23</td>
<td>11</td>
<td>11</td>
<td>4</td>
<td>10</td>
<td>13 (72)</td>
<td>10</td>
<td>13 (72)</td>
<td>13 (72)</td>
<td>2 (9)</td>
<td>2 (9)</td>
<td></td>
</tr>
<tr>
<td>Hayashi et al, 2008 \textsuperscript{5}</td>
<td>33</td>
<td>25</td>
<td>8</td>
<td>NR</td>
<td>9 (27)</td>
<td>9 (27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suzuki et al, 2009 \textsuperscript{79}</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>2</td>
<td>40 (30)</td>
<td>2</td>
<td>40 (30)</td>
<td>40 (30)</td>
<td>3 (60)</td>
<td>3 (60)</td>
<td></td>
</tr>
<tr>
<td>Sem et al, 2009 \textsuperscript{87}</td>
<td>11</td>
<td>8</td>
<td>7</td>
<td>2</td>
<td>11</td>
<td>1</td>
<td>7 (64)</td>
<td>7 (64)</td>
<td>1</td>
<td>7 (64)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalluri et al, 2009 \textsuperscript{81}</td>
<td>31</td>
<td>1</td>
<td>9</td>
<td>11</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Mukae, 2009 \textsuperscript{84}</td>
<td>27</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>NR</td>
<td>6 (22)</td>
<td>6 (22)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hervier et al, 2010 \textsuperscript{35}</td>
<td>17</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>6 (60)</td>
<td>3</td>
<td>6 (60)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koreeda et al, 2010 \textsuperscript{14}</td>
<td>14</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>12 (86)</td>
<td>12 (86)</td>
<td>12 (86)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ji et al, 2010 \textsuperscript{7}</td>
<td>69</td>
<td>23</td>
<td>16</td>
<td>7</td>
<td>6</td>
<td>2</td>
<td>36</td>
<td>NR</td>
<td>24 (34)</td>
<td>24 (34)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morganroth et al, 2010 \textsuperscript{82}</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4 (100)</td>
<td>4 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lega et al, 2010 \textsuperscript{50}</td>
<td>22</td>
<td>9</td>
<td>4</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>14 (64)</td>
<td>14 (64)</td>
<td>1 (5)</td>
<td>1 (5)</td>
<td></td>
</tr>
<tr>
<td>Marie et al, 2011 \textsuperscript{17}</td>
<td>107</td>
<td>56</td>
<td>25</td>
<td>38</td>
<td>6</td>
<td>90 (84)</td>
<td>90 (84)</td>
<td>90 (84)</td>
<td>90 (84)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bakewell and Raghu, 2011 \textsuperscript{90}</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>100 (100)</td>
<td>100 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muro et al, 2012 \textsuperscript{46}</td>
<td>10</td>
<td>5</td>
<td>3</td>
<td>6</td>
<td>10</td>
<td>100 (100)</td>
<td>10</td>
<td>100 (100)</td>
<td>100 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kunimasa et al, 2012 \textsuperscript{24}</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2 (100)</td>
<td>2</td>
<td>2 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ingegnoli et al, 2012 \textsuperscript{84}</td>
<td>15</td>
<td>3</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>27 (NR)</td>
<td>4</td>
<td>27 (NR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cao et al, 2012 \textsuperscript{38}</td>
<td>15</td>
<td>1</td>
<td>13</td>
<td>1</td>
<td>2</td>
<td>NR</td>
<td>4 (27)</td>
<td>4 (27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marie et al, 2013 \textsuperscript{15}</td>
<td>66</td>
<td>31</td>
<td>17</td>
<td>27</td>
<td>6</td>
<td>55 (83)</td>
<td>55 (83)</td>
<td>55 (83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** IVIG, intravenous immunoglobulin; NR, not reported.
Rituximab, a monoclonal antibody directed against the B cell surface marker CD20, has demonstrated some efficacy in treating ILD in a group of anti-Jo-1–positive patients after 6 months in combination with prednisone; however, the true utility of rituximab was hard to evaluate since the majority of patients had received various other immunosuppressant agents both before and after rituximab was used.67

Based on evidence implicating a possible role for TNF-α in the immunopathology of IIM, investigators have also used the TNF inhibitor adalimumab to successfully treat Jo-1 antibody-positive ILD.88 In addition, there have been reports of DM/PM–associated ILD that is refractory to high-dose steroids and CsA treated successfully with intravenous immunoglobulin,89,90 though significant data on the utility of such treatment are still lacking.

Clinical Course

Because myositis-associated ILD is a rare condition, most outcome analyses are reflective of case series or small, poorly controlled studies. Nevertheless, the available evidence suggests that outcomes in DM/PM and the antisynthetase syndrome are largely driven by the ILD phenotype, and to some extent, the presence of specific autoantibodies. Multiple reports have shown that patients with acute/subacute ILD in C-ADM often do not respond to therapy with corticosteroids and other immunosuppressive agents.4,10,44,91 By contrast, patients with radiologic or histologic evidence of an NSIP or COP pattern tend to be more responsive to steroid therapy.15,67 Furthermore, the presence of ARS antibodies in patients with ILD may predict greater steroid responsiveness, though with an increased risk of recurrence.78

Fathi et al followed patients with DM/PM ILD for 35 months after the initiation of treatment with corticosteroids plus another immunosuppressive agent and found that TLC improved in 38% of patients and deteriorated in 28%, with the remaining patients being labeled as stable. Interestingly, there were also several patients in whom PFTs normalized despite persistent radiographic abnormalities.8 In a similar DM/PM population, Won Huh et al demonstrated increased PVC and DLCO 6 months following treatment, an improvement that was sustained for up to 3 years.4 Likewise, Marie et al evaluated 107 patients with DM/PM ILD and found resolution in 32.7% and improvement in 51.4% with only 15.9% of patients deteriorating.67 Koreeda et al reported improvement in 12 out of 14 patients with ARS antibodies treated with either steroids or CsA, though there was one case of progressive worsening and death despite an initial improvement at 6 months.14

Treatment results in ARS antibody-positive patients may be more favorable, with evidence that an NSIP or COP pattern on HRCT confers a greater probability of steroid responsiveness in anti-Jo-1 patients with ILD.15 In a cohort of 28 anti-Jo-1 patients with ILD, for example, there was resolution in 25%, clinical improvement or stability in 54%, and worsening in 21%.32 Other studies of anti-Jo-1 ILD patients have shown similar results, with remission noted in 29% of patients and improvement or stabilization in upward of two-thirds of patients, the majority of which were treated with either corticosteroids or a combination of corticosteroids plus immunosuppressive drugs.26,92 Furthermore, Marie et al demonstrated resolution of rapidly progressive, acute onset ILD in 8 of 12 anti-Jo-1 patients treated with steroids and either CsA, azathioprine, or mycophenolate.15 Conversely, Ingegnoli et al showed less promising outcomes in a group of 15 patients with anti-Jo-1 PM; 60% had a worsening of their ILD 12 months after diagnosis.84 Finally, although a group of patients with anti-PL-7 antibodies showed some improvement with treatment in 64.3% of cases, no patients experienced frank resolution—a pattern also seen in some patients with nonspecified DM/PM or anti-Jo-1–associated ILD.34

Overall, the biggest factor determining survival rates in patients with DM/PM and the antisynthetase syndrome is the presence of ILD. Marie et al demonstrated an overall mortality rate of 7.5% for myositis-associated ILD, with 87.5% of deaths attributable to the patients’ lung disease.67 Ji et al showed a DM/PM mortality rate of 34.8% in patients with ILD versus 8.6% in patients without ILD.7 Similarly, the mortality rate among DM/PM patients in a Chinese cohort was 43.9% in patients with ILD versus 24.5% in patients without ILD.6 Finally, Hayashi et al demonstrated a mortality rate of 12% in PM ILD patients versus 44% in DM ILD patients, with most of the deaths in the DM group attributable to rapidly progressive lung disease.3 Indeed, acute ILD seems to portend a much worse prognosis than its chronic counterpart,3,7 with early (2 months) mortality rates as high as 72.7% in some cohorts of DM/PM ILD patients.4

Conclusions

The IIMs are a group of connective tissue diseases that include PM, DM, and ADM. Over the years, various MSAs have been identified, and their presence is associated with varying clinical phenotypes and propensities for the development of ILD. ILD in patients with DM/PM is associated with significant morbidity and mortality, and treatment typically consists of high-dose corticosteroids, often in conjunction with additional immunosuppressive agents. Although a majority of patients with ILD demonstrate either stability or improvement following treatment, there remains a subset of patients with fatal progression of their pulmonary disease. Further research in this field will require more detailed molecular profiling, more rigorous standardization of clinical data collection, improved consensus regarding outcome measures, and more balanced data sharing between institutions. The result will hopefully be a better understanding of the mechanisms underlying ILD, leading to more effective and targeted therapies.

References


Seminars in Respiratory and Critical Care Medicine Vol. 35 No. 2/2014
11 Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Pulmonary Manifestations of Polymyositis/Dermatomyositis Hallowell et al.
40 Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive
interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010;11:223
41 Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-
42 melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012;51(7):1278–1284
47 Muro Y, Suguri K, Hoshino K, Akiyama M. Disappearance of anti-
53 Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti- ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012; 2012:415272
60 Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with anti-
63 Wang HB, Zhang Y, Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001;29(12):2517–2521
64 Chinyo H, Salway F, Fertig N, et al; UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006;8(1):R13
72 Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010;138(6):1464–1474
sandhya p, keshava sn, danda d, padhan p, mathew j, ghibikote s. pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in south india. rheumatol int 2012;32(5):1415–1419

sato s, kuwana m,hirakata m. clinical characteristics of japanese patients with anti-oi (anti-isoleucyl-tRNA synthetase autoantibodies. rheumatology (oxford) 2007;46(5):842–845

yoshifuji h, fuji t, kobayashi s, et al. anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. autoimmunity 2006;39(3):233–241

hamaguchi y, kuwana m, hoshino k, et al. clinical correlations with dermatomyositis-specific autoantibodies in adult japanese patients with dermatomyositis: a multicenter cross-sectional study. arch dermatol 2011;147(4):391–398

kameda h, nagasawa h, ogawa h, et al. combination therapy with corticosteroids, cyclosporin a, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. j rheumatol 2005;32(9):1719–1726

swigris j, olson al, fischer a, et al. mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. chest 2006;130(1):30–36

morganroth pa, kreider me, werth vp. mycophenolate mofetil for interstitial lung disease in dermatomyositis. arthritis care res (hoboken) 2010;62(10):1496–1501

yamasaki y, yamada h, yamasaki m, et al. intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. rheumatology (oxford) 2007;46(1):124–130

ingegnoli f, lubatti c, ingegnoli a, boracchi p, zeni s, meroni pl. interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. autoimmun rev 2012;11(5):335–340


bakewell CJ, Raghuc G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. chest 2011;139(2):441–443


koenig M, fritzler MJ, targoff IN, Troyanov Y, senécal JL. heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. arthritis res ther 2007;9(4):R78